ADC Therapeutics SA (NYSE: ADCT) has announced updated data from the LOTIS-7 Phase 1b open-label clinical trial, which evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The data will be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The trial results indicate a clinically meaningful benefit, with an overall response rate of 93.3% and a complete response rate of 86.7% among 30 evaluable patients. The combination treatment is generally well-tolerated, with a manageable safety profile, and the company is expanding the study enrollment to 100 patients at a 150 µg/kg dose. The data will also be shared at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. ADC Therapeutics will host a conference call to discuss these results.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。